Modellierung von Hirntumoren in vivo unter Verwendung der elektroporationsbasierten Verabreichung von Plasmid-DNA, die die Mutationssignaturen von Patienten repräsentiert

Overview

This protocol describes a method for generating brain tumor mouse models that accurately represent common patient mutations in glioblastoma. By utilizing an immunocompetent, autochthonous tumor model, researchers can better predict treatment efficacy, particularly for immunotherapy.

Key Study Components

Area of Science

• Neuroscience
• Oncology
• Immunotherapy

Background

• Glioblastoma is characterized by aggressive cancer behavior.
• Genetic driver mutations influence tumor microenvironment and treatment response.
• Current preclinical models often fail to predict patient outcomes.
• Immunocompetent models provide a more accurate representation of human disease.

Purpose of Study

• To create a mouse model that mimics patient glioblastoma mutations.
• To study the impact of these mutations on tumor growth and treatment response.
• To enhance the predictive power of preclinical trials for immunotherapy.

Methods Used

• Electroporation-based delivery of plasmid DNA.
• Integration of DNA plasmids into the genome of immunocompetent mice.
• Gradual autochthonous tumor growth modeling.
• Genomic and single-cell sequencing for mutation profiling.

Main Results

• Successful modeling of patient mutation profiles in glioblastoma.
• Identification of immune cell populations associated with tumor behavior.
• Demonstrated efficacy of immunotherapy in preclinical trials.
• Highlighted discrepancies between mouse models and patient outcomes.

Conclusions

• The developed model provides a reliable platform for testing immunotherapeutic strategies.
• It allows for better understanding of tumor microenvironment interactions.
• Future studies can leverage this model to improve patient treatment strategies.

Frequently Asked Questions